Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Camcolit

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 77Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ameerex Signs 551K-Ton LCE Deal With Patagonia Lithium
    Ameerex Signs 551K-Ton LCE Deal With Patagonia Lithium

    07 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-07/ameerex-enters-strategic-partnership-with-patagonia-lithium-asx-pl3-gaining-exposure-to-inferred

    PHARMIWEB
    07 Jan 2026
    Share Share
    Alzamend Neuro Starts Phase II AL001 Trial at Hospital
    Alzamend Neuro Starts Phase II AL001 Trial at Hospital

    13 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/13/3080073/0/en/Alzamend-Neuro-Initiates-First-Phase-II-Clinical-Trial-of-AL001-Lithium-in-Brain-Study-Taking-Place-at-Massachusetts-General-Hospital.html

    GLOBENEWSWIRE
    13 May 2025
    Share Share
    Alzamend Reports Lithium Exposure Study in Alzheimer’s Mice
    Alzamend Reports Lithium Exposure Study in Alzheimer’s Mice

    19 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241119240778/en

    BUSINESSWIRE
    19 Nov 2024
    Share Share
    Sanofi offloads rights to prolonged-release antipsychotic drug
    Sanofi offloads rights to prolonged-release antipsychotic drug

    27 Apr 2022

    // Nick Paul Taylor FIERCEPHARMA

    https://www.fiercepharma.com/pharma/sanofi-offloads-rights-prolonged-release-antipsychotic-drug

    Nick Paul Taylor FIERCEPHARMA
    27 Apr 2022
    Share Share
    Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO
    Preclinical Alzheimer's biotech Alzamend Neuro files for a $12 million IPO

    11 May 2021

    // RENAISSANCECAPITAL

    https://www.renaissancecapital.com/IPO-Center/News/81644/Preclinical-Alzheimers-biotech-Alzamend-Neuro-files-for-a-$12-million-IPO#:~:text=Alzamend%20Neuro%2C%20a%20preclinical%20biotech,in%20an%20initial%20public%20offering.

    RENAISSANCECAPITAL
    11 May 2021
    Share Share
    Intra-Cellular's Caplyta could cruise toward bipolar depression win
    Intra-Cellular's Caplyta could cruise toward bipolar depression win

    09 Sep 2020

    // Angus Liu FIERCE PHARMA

    https://www.fiercepharma.com/marketing/intra-cellular-s-caplyta-could-cruise-toward-blockbuster-land-bipolar-depression-win

    Angus Liu FIERCE PHARMA
    09 Sep 2020
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.